# A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

Study · id `cardio:ct-nct06215911` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06215911](<https://clinicaltrials.gov/study/NCT06215911>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06215911

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.

## Technical summary

Registry record NCT06215911. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-13 (actual); primary completion 2025-10-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 557 participants (enrolled count; ClinicalTrials.gov record NCT06215911, source copy `cardio:ctgov-nct06215911-2026-09-01`, retrieved 2026-10-26)
- Started: 2024-02-13 (actual) (ClinicalTrials.gov record NCT06215911, source copy `cardio:ctgov-nct06215911-2026-09-01`, retrieved 2026-10-26)
- Primary completion: 2025-10-10 (actual) (ClinicalTrials.gov record NCT06215911, source copy `cardio:ctgov-nct06215911-2026-09-01`, retrieved 2026-10-26)
- Completion: 2025-10-10 (actual) (ClinicalTrials.gov record NCT06215911, source copy `cardio:ctgov-nct06215911-2026-09-01`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Bulgaria; Canada; Czechia; Georgia; Germany; Hungary; Italy; Latvia; Lithuania; Netherlands; New Zealand; Poland; Slovakia; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06215911, source copy `cardio:ctgov-nct06215911-2026-09-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06215911-2026-09-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
- Acronym: Cycle-1-REF
- Condition: Heart Failure
- Condition: Heart Failure With Reduced Ejection Fraction
- Condition: Cardiovascular Diseases
- Condition: Heart Diseases
- Intervention (Drug): Tovinontrine (CRD-750)
- Intervention (Drug): Placebo
- Lead sponsor: Cardurion Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Cardurion Pharmaceuticals, Inc. (`cardio:org-cardurion-pharmaceuticals-inc`)

## Provenance

Content hash: b1a56c10b6bd7fa6bb06d4709441181c7f92d48250ed174cc87123721d2a178c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
